Prelude Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate KAT6A Selective Degrader PRT13722 in Combination with Verzenio® and Inluriyo® in Patients with HR+/HER2- Breast Cancer
Prelude Therapeutics announced a clinical trial collaboration and supply agreement with Eli Lilly to evaluate its KAT6A selective degrader PRT13722 in combination with abemaciclib (Verzenio) and imlunestrant (Inluriyo) in HR+/HER2- breast cancer. The FDA recently cleared the Phase 1 IND for PRT13722, with monotherapy dose escalation beginning in Q4 2026 followed by combination cohorts. Preclinical data presented at AACR 2026 showed monotherapy efficacy and synergy with CDK4/6 inhibitors and endocrine therapies.
Key figures
- Drug Name
- PRT13722 (oral KAT6A selective degrader)
- Phase Of Trial
- Phase 1
- Ind status
- FDA cleared Phase 1 study to proceed
- Enrollment start
- Q4 2026
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.